Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript
Syntara Limited held a shareholder and analyst call on April 29, 2026, to discuss FDA feedback on its Phase IIb trial of amsulostat for myelofibrosis, a recent capital raising, and its quarterly report filed with the ASX. CEO Gary Phillips provided an overview of the company's progress and regulatory developments. The call included a presentation and a Q&A session for participants to seek further details.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4896346-syntara-limited-pmxsf-shareholder-analyst-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
